The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib

od Medina, Theresa M, Lewis, Karl D
Izdano u Onco Targets Ther (2016)

BRAF/MEK inhibitor-induced remission of primary cutaneous myoepithelial carcinoma after local recurrence

od Guidry, Jacqueline, Lewis, Karl, Brown, Mariah
Izdano u JAAD Case Rep (2020)

Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review

od Okuyama, Sonia, Gonzalez, Rene, Lewis, Karl D
Izdano 2010

Therapeutic options in cutaneous melanoma: latest developments

od Amaria, Rodabe N., Lewis, Karl D., Gonzalez, Rene
Izdano 2011

The contribution of bone and cartilage to the near-infrared spectrum of osteochondral tissue

od McGoverin, Cushla M., Lewis, Karl, Yang, Xu, Bostrom, Mathias P. G., Pleshko, Nancy
Izdano u Appl Spectrosc (2014)

A neoadjuvant biochemotherapy approach to stage III melanoma; analysis of surgical outcomes

od Kounalakis, Nicole, Gao, Dexiang, Gonzalez, Rene, Becker, Maude, Lewis, Karl, Poust, Jamie, Pearlman, Nathan, Robinson, William, McCarter, Martin
Izdano 2012

Twist1 Inactivation in Dmp1-Expressing Cells Increases Bone Mass but Does Not Affect the Anabolic Response to Sclerostin Neutralization

od Lewis, Karl J., Choi, Roy B-J, Pemberton, Emily Z., Bullock, Whitney A., Firulli, Anthony B., Robling, Alexander G.
Izdano u Int J Mol Sci (2019)

The mTORC2 Component Rictor Is Required for Load‐Induced Bone Formation in Late‐Stage Skeletal Cells

od Lewis, Karl J, Yi, Xin, Wright, Christian S, Pemberton, Emily Z, Bullock, Whitney A, Thompson, William R, Robling, Alexander G
Izdano u JBMR Plus (2020)

Bridging the transition from cancer patient to survivor: Pilot study results of the Cancer Survivor Telephone Education and Personal Support (C-STEPS) program

od Garrett, Kathleen, Okuyama, Sonia, Jones, Whitney, Barnes, Denise, Tran, Zung, Spencer, Lynn, Lewis, Karl, Maroni, Paul, Chesney, Margaret, Marcus, Al
Izdano u Patient Educ Couns (2013)

Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients

od Park, Song Y., Church, Candice, Alexander, Nora A., Shinohara, Michi M., Paulson, Kelly G., Lewis, Karl D., Lee, Nancy S., Nghiem, Paul
Izdano u JAAD Case Rep (2020)

Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control

od Stinauer, Michelle A, Kavanagh, Brian D, Schefter, Tracey E, Gonzalez, Rene, Flaig, Thomas, Lewis, Karl, Robinson, William, Chidel, Mark, Glode, Michael, Raben, David
Izdano 2011

Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.

od Tobin, Richard P., Jordan, Kimberly R., Robinson, William A., Davis, Dana, Borges, Virginia F., Gonzalez, Rene, Lewis, Karl D., McCarter, Martin D.
Izdano u Int Immunopharmacol (2018)

Spatial mapping of polymicrobial communities reveals a precise biogeography associated with human dental caries

od Kim, Dongyeop, Barraza, Juan P., Arthur, Rodrigo A., Hara, Anderson, Lewis, Karl, Liu, Yuan, Scisci, Elizabeth L., Hajishengallis, Evlambia, Whiteley, Marvin, Koo, Hyun
Izdano u Proc Natl Acad Sci U S A (2020)

ABT-737 synergizes with Bortezomib to kill melanoma cells

od Reuland, Steven N., Goldstein, Nathaniel B., Partyka, Katie A., Smith, Shilo, Luo, Yuchun, Fujita, Mayumi, Gonzalez, Rene, Lewis, Karl, Norris, David A., Shellman, Yiqun G.
Izdano 2011

Correlation between early FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma

od Schmitt, Ronald J, Kreidler, Sarah M, Glueck, Deborah H, Amaria, Rodabe N, Gonzalez, Rene, Lewis, Karl, Bagrosky, Brian M, Kwak, Jennifer J, Koo, Phillip J
Izdano u Nucl Med Commun (2016)

Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma

od Chang, Anne Lynn S., Lewis, Karl D., Arron, Sarah T., Migden, Michael R., Solomon, James A., Yoo, Simon, Day, Bann-Mo, McKenna, Edward F., Sekulic, Aleksandar
Izdano u Oncotarget (2016)

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer

od Zhou, Qing, Gustafson, Daniel, Nallapareddy, Sujatha, Diab, Sami, Leong, Stephen, Lewis, Karl, Gore, Lia, Messersmith, Wells A., Treston, Anthony M., Eckhardt, S. Gail, Sidor, Carolyn, Camidge, D. Ross
Izdano u Invest New Drugs (2010)

Osteocyte calcium signals encode strain magnitude and loading frequency in vivo

od Lewis, Karl J., Frikha-Benayed, Dorra, Louie, Joyce, Stephen, Samuel, Spray, David C., Thi, Mia M., Seref-Ferlengez, Zeynep, Majeska, Robert J., Weinbaum, Sheldon, Schaffler, Mitchell B.
Izdano u Proc Natl Acad Sci U S A (2017)

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials

od Hauschild, Axel, Larkin, James, Ribas, Antoni, Dréno, Brigitte, Flaherty, Keith T., Ascierto, Paolo A., Lewis, Karl D., McKenna, Edward, Zhu, Qian, Mun, Yong, McArthur, Grant A.
Izdano u JAMA Oncol (2018)

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled a...

od Ascierto, Paolo A., Ribas, Antoni, Larkin, James, McArthur, Grant A., Lewis, Karl D., Hauschild, Axel, Flaherty, Keith T., McKenna, Edward, Zhu, Qian, Mun, Yong, Dréno, Brigitte
Izdano u J Transl Med (2020)